Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 20, Issue 11, Pages 1389-1392Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14728222.2016.1238899
Keywords
Antidepressant; esketamine; hydroxynorketamine; ketamine; (R)-ketamine
Categories
Funding
- Grants-in-Aid for Scientific Research [24116006] Funding Source: KAKEN
Ask authors/readers for more resources
The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine is one of the most attractive antidepressants since this drug causes rapid-onset and sustained antidepressant effects in treatment resistant patients with depression. There are unanswered questions about how ketamine induces its rapid and sustained antidepressant actions. This key article suggests that (2R,6R)-HNK (hydroxynorketamine), a major metabolite of (R)-ketamine, shows antidepressant effects in rodent models of depression, indicating that the metabolism of (R)-ketamine to (2R,6R)-HNK is pivotal in its antidepressant action. Here these findings are put into context and their significance is discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available